Editorials

Misoprostol for the management of postpartum haemorrhage

BMJ 2011; 342 doi: http://dx.doi.org/10.1136/bmj.d2877 (Published 13 May 2011) Cite this as: BMJ 2011;342:d2877
  1. Anisa Elati, research fellow,
  2. Andrew Weeks, senior lecturer in obstetrics
  1. 1School of Reproductive and Developmental Medicine, University of Liverpool, Liverpool Women’s Hospital, Liverpool L8 7SS, UK
  1. aweeks{at}liverpool.ac.uk

No benefit if oxytocin is available, but useful where no other alternatives exist

For decades, oxytocin and ergometrine have been the treatments of choice for postpartum haemorrhage caused by ineffective uterine contraction (uterine atony). Although both drugs are effective, oxytocin is more widely used because it has fewer side effects and can be used safely in women with hypertension and pre-eclampsia. However, in their usual form both drugs can be given only by injection, and both require refrigeration. They are therefore of limited availability and benefit in low resource settings, especially in rural areas. Misoprostol, an orally active and heat stable prostaglandin E1 analogue, has therefore emerged as a popular alternative. Until a year ago, there was limited evidence for its ability to treat postpartum haemorrhage.1 2 However proponents have argued that it should be “parachuted in” to high risk areas despite the lack of evidence.3 This, in part, has been responsible for its inclusion in multiple guidelines on postpartum haemorrhage both in rich and poor settings (despite the call in a systematic review for more studies2).

Since the systematic review of the treatment of postpartum haemorrhage was last updated in 2007,2 three large double blind randomised trials have been published.4 5 6 Few research …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe